Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled GM-CSF in Autoimmune PAP
NCT02243228Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2014
- Primary completion
- Aug 2017
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sargramostim in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by Peking Union Medical College Hospital. Primary endpoint: Alveolar-arterial oxygen difference at 2 years. Status: unknown.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on NCT02243228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243228.